Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 DCV/ASV/BMS-791325 Fixed-Dose Combination in Japanese Subjects With Genotype 1 Chronic Hepatitis C
jRCT2080222495Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclabuvir, daclatasvir and asunaprevir in hepatitis C virus infection (3 arms), sponsored by Bristol Myers Squibb.
02
Drugs
beclabuvirdaclatasvirasunaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on jRCT2080222495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222495.